$ Value
$14K
Shares
3,525
Price
$4
Filed
Feb 11
Insider
Name
Carter Todd Alfred
Title
Chief Scientific Officer
CIK
0001944011
Roles
Transaction Details
Transaction Date
2026-02-10
Code
S
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
153,193
Footnotes
Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 9, 2026. The sales do not represent a discretionary trade by the reporting person. | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.71 to $3.91, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Filing Info
Carter Todd Alfred's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-02-24 | VYGR | ▼ | $16K |
| 2026-02-18 | VYGR | ▼ | $11K |
| 2026-02-10 | VYGR | ▼ | $14K |
| 2026-02-06 | VYGR | A | $0 |
| 2026-02-06 | VYGR | A | $0 |
Other Insiders at VYGR (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
Sandrock Alfred
President and CEO
|
— | $184K | 2026-04-02 |
|
Jorgensen Nathan D.
Chief Financial Officer
|
— | $18K | 2026-02-24 |
|
Swartz Robin
COO & CBO
|
— | $55K | 2026-02-24 |
|
Carter Todd Alfred
Chief Scientific Officer
|
— | $27K | 2026-02-24 |
|
Ferguson Toby
Chief Medical Officer
|
— | — | 2026-02-06 |
|
Shiferman Gregory L.
SVP and General Counsel
|
— | — | 2026-04-01 |